Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). · 2021
Read Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. by Early Breast Cancer Trialists’ Collaborative group (EBCTCG). (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8324484.txt.
Description
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) pools trial data on trastuzumab for early HER2-positive breast cancer. The drug targets the HER2 protein's outer domain. Added to chemotherapy, it cuts recurrence and death, but can harm the heart.
The group gathered patient-level data from seven randomised trials. The pool held 13,864 women with operable breast cancer. Both node-negative and node-positive cases entered. Long-term gains were set against cause-specific deaths. Cardiac risk was weighed in the same frame. Such pooled work gives the firmest long view of a drug's worth. Operable, early-stage disease was the shared trial frame.
Catalog record
| CREATOR | Early Breast Cancer Trialists’ Collaborative group (EBCTCG). |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |